The future of cancer treatment: will it include immunotherapy?
Negative immune regulatory pathways inhibit anti-cancer T cell responses, preventing effective immune surveillance. Two clinical trials using monoclonal antibodies that antagonize the PD-1/PD-L1 pathway recently reported regression in several tumor types. In one of these trials, efficacy was linked to the expression of the PD-L1 biomarker on tumor cells.
Diabetes Center, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA. jeff.bluestone@ucsf.edu
Jeffrey A
JA
Bluestone
Eric J
EJ
Small